Condition: Primary Immune Thrombocytopenia · Sponsor: Pfizer
This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP
This description comes directly from the study's public registry record.
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
Always discuss trial participation with your own doctor first.
| East Carolina University | Greenville, North Carolina, United States | Recruiting |
| Liverpool Hospital | Liverpool, New South Wales, Australia | Recruiting |
| South West Radiology | Liverpool, New South Wales, Australia | Recruiting |
| Slade Pharmacy | Mount Kuring-Gai, New South Wales, Australia | Recruiting |
| Calvary Mater Newcastle | Waratah, New South Wales, Australia | Recruiting |
| Flinders Medical Centre | Bedford Park, South Australia, Australia | Recruiting |
| ICON Cancer Centre - Kurralta Park | Kurralta Park, South Australia, Australia | Recruiting |
| The Alfred Hospital | Melbourne, Victoria, Australia | Recruiting |
| Royal Perth Hospital | Perth, Western Australia, Australia | Recruiting |
| Unity Health Toronto, St. Michael's Hospital | Toronto, Ontario, Canada | Recruiting |
| McGill University Health Centre | Montreal, Quebec, Canada | Recruiting |
| Fakultni nemocnice Hradec Kralove | Hradec Králové, Czechia | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05070845